John Strickler

Positions:

Associate Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2005

The University of Chicago

Residency, Medicine

University of Washington

Fellowship in Hematology-Oncology, Medicine

Duke University School of Medicine

Grants:

A Phase 1/1b first-in-human dose escalation and expansion study for theevaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with REGN2810 in adult

Administered By
Duke Cancer Institute
Awarded By
Sanofi US
Role
Principal Investigator
Start Date
End Date

A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors

Administered By
Duke Cancer Institute
Awarded By
Curegenix Inc.
Role
Principal Investigator
Start Date
End Date

A PHASE Ib, MULTICENTER, OPEN-LABELSTUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF CIBISATAMAB IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT WITH OBINUTUZUMAB IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC, MICROSATELLITE-STABL

Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Role
Principal Investigator
Start Date
End Date

A PHASE 1/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY OF NKTR-262 IN COMBINATION WITH NKTR-214 AND IN COMBINATION WITH NKTR-214 PLUS NIVOLUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES

Administered By
Duke Cancer Institute
Awarded By
Nektar Therapeutics
Role
Principal Investigator
Start Date
End Date

Phase 2 Study Comparing Efficacy and Safety of ABT-165 plus FOLFIRI vs Bevacizumab plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab

Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Role
Principal Investigator
Start Date
End Date

Publications:

1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress)

Authors
Park, H; Bekaii-Saab, T; Kim, S; Kamath, S; Pishvaian, M; Ford, J; Zhen, D; Mayor, J; Lux, C; Tan, Q; Strickler, J
URI
https://scholars.duke.edu/individual/pub1498580
Source
crossref
Published In
Annals of Oncology
Volume
32
Published Date
Start Page
S1073
End Page
S1074
DOI
10.1016/j.annonc.2021.08.1546

439P Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study

Authors
Strickler, JH; Hsu, L-I; DeBusk, K; Wright, P; Stecher, M; Siadak, M; Palanca-Wessels, MC; Yu, J; Zhang, N; Espenschied, CR; Lang, K; Bekaii-Saab, T
MLA Citation
Strickler, J. H., et al. “439P Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S554–S554. Crossref, doi:10.1016/j.annonc.2021.08.960.
URI
https://scholars.duke.edu/individual/pub1498883
Source
crossref
Published In
Annals of Oncology
Volume
32
Published Date
Start Page
S554
End Page
S554
DOI
10.1016/j.annonc.2021.08.960

1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress

Authors
Catenacci, DV; Strickler, JH; Shitara, K; Nakamura, Y; Janjigian, YY; Barzi, A; Bekaii-Saab, T; Lenz, HJ; Chung, HC; Tabernero, J; Yoshino, T; Siena, S; Mayor, JG; Palanca-Wessels, MC; Xie, D; Marshall, JL
MLA Citation
Catenacci, D. V., et al. “1434TiP MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress.” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S1071–72. Crossref, doi:10.1016/j.annonc.2021.08.1543.
URI
https://scholars.duke.edu/individual/pub1498884
Source
crossref
Published In
Annals of Oncology
Volume
32
Published Date
Start Page
S1071
End Page
S1072
DOI
10.1016/j.annonc.2021.08.1543

434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)

Authors
Fakih, M; Falchook, GS; Hong, DS; Yaeger, RD; Chan, E; Mather, O; Cardona, P; Dai, T; Strickler, J
MLA Citation
URI
https://scholars.duke.edu/individual/pub1498885
Source
crossref
Published In
Annals of Oncology
Volume
32
Published Date
Start Page
S551
End Page
S551
DOI
10.1016/j.annonc.2021.08.955

First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.

<h4>Lessons learned</h4>Inhibition of glycoprotein fucosylation, as monotherapy and in combination with immune checkpoint blockade, is a promising therapeutic strategy for treating a broad range of cancers. In this first-in-human, first-in-class, phase I study in advanced solid tumors, SGN-2FF demonstrated dose-proportional pharmacokinetics, evidence of pharmacodynamic target inhibition of glycoprotein fucosylation, and preliminary antitumor activity. SGN-2FF was associated with thromboembolic events that led to study termination.<h4>Background</h4>We conducted a first-in-human, first-in-class, phase I study of SGN-2FF, a potent small-molecule inhibitor of glycoprotein fucosylation, in patients with advanced solid tumors.<h4>Methods</h4>The study consisted of four parts: SGN-2FF monotherapy dose-escalation (part A) and expansion (part B), and SGN-2FF + pembrolizumab dose-escalation (part C) and expansion (part D). The objectives were to evaluate safety and tolerability, maximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of SGN-2FF monotherapy and SGN-2FF + pembrolizumab.<h4>Results</h4>Forty-six patients were enrolled (part A, n = 33; part B, n = 6; part C, n = 7; part D did not enroll any patients). During part A (n = 32) exploring 1-15 g once daily (QD) and 2-5 g twice daily (b.i.d.), grade 3 dose-limiting toxicities were diarrhea (2 g and 15 g QD) and increased lipase (2 g QD). The MTD was 10 g daily. In part A, common toxicities were grades 1-2 diarrhea, fatigue, and nausea (each 47%); thromboembolic events (grades 2-5) occurred in 5 of 32 patients (16%). Safety measures included concurrent prophylactic anticoagulation with low-molecular weight heparin (LMWH). In part C, despite the safety measures implemented, a thromboembolic event occurred in one of seven patients (14%) during the SGN-2FF lead-in period. Of 28 evaluable patients in part A, 1 patient with advanced head and neck squamous cell carcinoma achieved Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 complete response (CR) and 10 (36%) had RECIST v1.1 stable disease, including 1 patient with advanced triple-negative breast cancer with 51% tumor burden reduction. SGN-2FF administration led to dose-proportional increases in exposure and PD reduction in protein fucosylation.<h4>Conclusion</h4>SGN-2FF demonstrated proof-of-mechanism and preliminary antitumor activity but was associated with thromboembolic events leading to study termination.
Authors
Do, KT; Chow, LQM; Reckamp, K; Sanborn, RE; Burris, H; Robert, F; Camidge, DR; Steuer, CE; Strickler, JH; Weise, A; Specht, JM; Gutierrez, M; Haughney, P; Hengel, S; Derleth, CL; Yap, TA
MLA Citation
Do, Khanh T., et al. “First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.The Oncologist, July 2021. Epmc, doi:10.1002/onco.13911.
URI
https://scholars.duke.edu/individual/pub1488775
PMID
34288257
Source
epmc
Published In
The Oncologist
Published Date
DOI
10.1002/onco.13911